Condition: Metastatic Castration-resistant Prostate Cancer · Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The objective of this study is to determine the safety and clinical effects of alternating pharmacologic (i.e. supraphysiologic) testosterone therapy with darolutamide in men with metastatic prostate cancer as first line hormonal therapy. Correlative studies will be conducted to assess the effect of alternating therapy on quality of life, gene expression and metabolic changes associated with alternating therapy.
This description comes directly from the study's public registry record.
Rana Sullivan, RN · 410-614-6337 · tomalra@jhmi.edu
Donna Bieg, RN · 410-502-7625 · dbieg2@jh.edu
Always discuss trial participation with your own doctor first.
| Johns Hopkins Sidney Kimmel Comprehensive Cancer Center | Baltimore, Maryland, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07142551